DEFA14A: Relay Therapeutics Sets Date for 2025 Annual Stockholders Meeting
Proxy Statement
Relay Therapeutics announces its annual stockholders meeting to be held on June 6, 2025, covering director elections, executive compensation, and auditor ratification.
Summary
- Relay Therapeutics will hold its annual meeting of stockholders on June 6, 2025.
- The meeting will address the election of two Class II directors to serve until the 2028 annual meeting.
- Stockholders will vote on an advisory resolution regarding the compensation of named executive officers.
- The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, will be ratified.
- The board of directors recommends voting 'FOR' Proposals 1, 2, and 3.
Sentiment
Score: 7
Explanation: The document is a routine announcement of an annual meeting, indicating standard corporate governance procedures. The sentiment is neutral to slightly positive as it reflects ongoing operations and shareholder engagement.
Positives
- The meeting provides stockholders with the opportunity to participate in key decisions regarding the company's governance.
- Stockholders can vote on director elections, executive compensation, and the selection of the company's auditor.
- The availability of proxy materials online enhances accessibility for stockholders.
Future Outlook
The proxy statement outlines the matters to be addressed at the upcoming annual meeting, focusing on governance and operational decisions for the company's future.
Industry Context
This announcement is a standard corporate procedure for publicly traded companies, ensuring shareholder participation in key decisions.
Stakeholder Impact
- Shareholders have the opportunity to influence company decisions through voting.
- The outcome of the votes will impact the composition of the board and the selection of the auditor.
Next Steps
- Stockholders should review the proxy materials and vote on the proposals.
- The company will proceed with the annual meeting on June 6, 2025.
- The elected directors will serve until the 2028 annual meeting.
Key Dates
| Date | Description |
|---|---|
| April 8, 2025 | Record date for stockholders eligible to vote at the annual meeting |
| May 27, 2025 | Deadline to request paper copies of proxy materials in time for the meeting |
| June 6, 2025 | Date of the Annual Meeting of Stockholders |
| December 31, 2025 | Fiscal year end for which Ernst & Young LLP's appointment is being ratified |
| 2028 | Year the term expires for the Class II directors being elected |
Keywords
Annual Meeting, Stockholders, Proxy Statement, Director Election, Executive Compensation, Auditor Ratification, Relay Therapeutics
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.